Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction.
about
Insights into the Regulatory Role of Non-coding RNAs in Cancer MetabolismPolycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular backgroundImmunometabolism of regulatory T cellsPD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinationsTumor Microenvironment Metabolism: A New Checkpoint for Anti-Tumor ImmunityMitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma.Inhibition of histone methyltransferase EZH2 ameliorates early acute renal allograft rejection in ratsGLUT1 and ASCT2 as Predictors for Prognosis of Hepatocellular CarcinomaEffector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian CancerIL-7 signaling imparts polyfunctionality and stemness potential to CD4(+) T cells.MicroRNA-491 regulates the proliferation and apoptosis of CD8(+) T cellsKLRG1 restricts memory T cell antitumor immunity.Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy.Reversing T-cell Dysfunction and Exhaustion in Cancer.Metabolic regulation of immune responses: therapeutic opportunities.T-cell metabolism governing activation, proliferation and differentiation; a modular view.Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting.Epigenetic control of the tumor microenvironment.Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.Filling the Tank: Keeping Antitumor T Cells Metabolically Fit for the Long Haul.Immunometabolism in systemic lupus erythematosus.Visualizing the life of mRNA in T cells.Structure of the PRC2 complex and application to drug discovery.Epigenetic Variability in Systemic Lupus Erythematosus: What We Learned from Genome-Wide DNA Methylation Studies.Metabolic Instruction of Immunity.Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy.Transcriptional and epigenetic regulation of T cell hyporesponsiveness.The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction.The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia.ASIATIC ACID INFLUENCES GLUCOSE HOMEOSTASIS IN P. BERGHEI MURINE MALARIA INFECTED SPRAGUE-DAWLEY RATS.Early transcriptional and epigenetic regulation of CD8+ T cell differentiation revealed by single-cell RNA sequencing.Epigenetic Reprogramming in Naive CD4+ T Cells Favoring T Cell Activation and Non-Th1 Effector T Cell Immune Response as an Early Event in Lupus FlaresImmune Cell Population in Ovarian Tumor Microenvironment.The tumor microenvironment disarms CD8+ T lymphocyte function via a miR-26a-EZH2 axis.Identification of inhibitors of myeloid-derived suppressor cells activity through phenotypic chemical screening.Immune checkpoint inhibitors in cancer therapy.Suppression of FIP200 and autophagy by tumor-derived lactate promotes naïve T cell apoptosis and affects tumor immunity.Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor.miRNAs, Melanoma and Microenvironment: An Intricate Network.Shifts in podocyte histone H3K27me3 regulate mouse and human glomerular disease.
P2860
Q26739857-3E43E598-E3DD-425B-AB46-2E4F106391F2Q26745416-977820FD-A588-49B4-A6E5-2BDBFE50F1B5Q28074509-B741A479-D631-4E76-9606-B25116FEC543Q28075712-E5C40FDF-9DA2-4A09-BA72-28576F7AB771Q28077647-9F1C0F51-2352-4B9E-9AB7-B008F571A678Q33798098-C6D553A3-05A3-4FB4-B358-630ED308354EQ36175311-8B8B1370-B9BC-4B80-8EE3-C7665E6AA5F8Q36236396-9E90A443-277E-4F41-A2D2-BAE82CECF1F0Q36922131-74FC5128-5DF4-43E8-A07D-4244AD0A588EQ37078985-173E789C-9603-48F5-B28E-9516B8DDDAFBQ37147870-5922B8E7-9A08-4658-B508-B215D1D16E5FQ37641660-EFEBD5E8-E313-4326-A5C0-DD50B51A7EC3Q38805897-773B04F2-02FB-4376-943E-DCE51AADD76EQ38809776-026CDC44-8DD0-43B1-8754-C02131040D83Q38850162-4BFEE2E9-6162-4EBF-AB1A-D57E0961AF67Q38915095-3B2CC392-7EB7-4387-8C56-E891C4FF4478Q38966736-C28DFA65-9798-4630-944E-A04FEFF79A99Q38971785-7A571CBE-70A3-4C72-B048-D5989DE05CAEQ38993869-C68F4FE5-C968-4286-B9FC-70627E6DBC5EQ39026430-2AA4D1AC-E485-4DC5-A187-EC3727E0B721Q39209701-67242BCB-50E8-48FC-8751-FAE6B0D27552Q39241592-932B2FB4-E117-4DE1-A684-FAAA202F6B8DQ39245946-66F2ED47-3713-4BC3-910B-E2055CC420E1Q39282560-66DC9EC8-B61D-4104-8E4F-39D69C768494Q39286043-F4AAE50E-D36E-447B-B124-5B1F7D324F55Q39337489-EF8B46E6-6C0E-415A-8D37-6B04D3D4A72BQ39367810-64666B5E-2EA9-4946-B64E-3B74216C52BEQ39518049-D734E5E2-3280-4606-8F08-544F3630E268Q39538318-6589D88A-3721-43DE-AEC4-F97A560F544FQ40219366-849EC3E3-43CD-4E8F-BAC1-540B24361D03Q40325436-79C1AB41-8E81-4443-8460-1F9A1030ED53Q40959199-19B02CC3-7627-4027-BA90-964D4423FEFDQ41721704-1DE9EA27-44F5-414F-A512-758745F83B36Q42333838-E918B681-7AFD-483C-8F02-EE862D659BFEQ45160017-8BC4A609-9D7E-4F08-BC17-216F7C08DADAQ45871487-ACAD3009-B942-4DD8-9F9D-54A281850EFEQ46259330-6097F57A-8B25-431D-B80D-3AB426DE0031Q46272404-00EE92AD-B7FA-439B-8D3E-F9E9C3CB0B0FQ47152593-907E94F6-300D-438B-9E9A-8D974AE7594FQ47308611-0CCDB26F-C804-4B9F-B83D-F94EF104CC51
P2860
Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Cancer mediates effector T cel ...... H2 via glycolysis restriction.
@ast
Cancer mediates effector T cel ...... H2 via glycolysis restriction.
@en
type
label
Cancer mediates effector T cel ...... H2 via glycolysis restriction.
@ast
Cancer mediates effector T cel ...... H2 via glycolysis restriction.
@en
prefLabel
Cancer mediates effector T cel ...... H2 via glycolysis restriction.
@ast
Cancer mediates effector T cel ...... H2 via glycolysis restriction.
@en
P2093
P2860
P50
P356
P1433
P1476
Cancer mediates effector T cel ...... ZH2 via glycolysis restriction
@en
P2093
Arul M Chinnaiyan
Guobin Wang
Hongbo Wang
Ilona Kryczek
Irene Shao
Jan Kotarski
Linda Vatan
P2860
P304
P356
10.1038/NI.3313
P407
P577
2015-11-02T00:00:00Z